Histone deacetylases (HDACs) play a key role in the regulation of gene expression and chromatin structure, and drugs targeting these enzymes might have an important impact in the treatment of human cancer. Herein, we report the characterization of (1H)-pyrroles as a new subfamily of HDAC inhibitors obtained by computational modeling of class-I human HDACs. From a functional standpoint, (1H )-pyrroles are powerful inductors of acetylation of histones H3 and H4, and restore the expression of growth-inhibitory genes. From a cellular view, these compounds cause a marked decrease in the viability of cancer cells in vitro and in vivo, associated with a cell-cycle arrest at G2/M and an inhibition of angiogenesis. Thus, (1H )-pyrroles emerge as a novel group of HDAC inhibitors with promising antitumoral features.
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These modifications have both direct effects and indirect architectural effects on a variety of nuclear processes, including gene transcription, and DNA repair and replication. It has been proposed that distinct histone modifications on one or more tails act sequentially, or in combination, to form a 'histone code', which is read by other proteins to bring about distinct downstream events (Jenuwein and Allis, 2001; Kouzarides, 2007) . Acetylation of histone lysines is generally associated with transcriptional activation (Jenuwein and Allis, 2001; Kouzarides, 2007) . Most importantly, these histone acetylation patterns are disrupted in human disease, such as cancer (Esteller, 2007) , neurological syndromes (Sadri-Vakili and Cha, 2006) and autoimmune disorders (Richardson, 2007) . Thus, there is an exponential emerging interest in the development of drugs that interfere with the histone acetylation reactions. Most importantly, two inhibitors of histone deacetylases (HDACs), suberoylanilide hydroxamic acid (SAHA) and MGCD0103, have received approval by the Food and Drug Administration for the treatment of hematological malignancies and lymphoproliferative disorders (Balakin et al., 2007) . Thus, biomedical and clinical researchers are eager to have at their disposal new HDAC inhibitors that, working at minimal concentration, cause a biochemical, cellular and a potentially therapeutic response.
We undertook the task of identifying a new subfamily of histone deacetylase inhibitors, using computational modeling. Two significant groups of X-ray structures have so far been reported in HDAC-inhibitor complexes. The first corresponds to an HDAC-like protein (obtained from Aquiflex aeolicus; AA-HDAC, hereafter) with SAHA and trichostatin A (TSA) (Finnin et al., 1999) . The second group of structures has been obtained from human HDAC8 and several inhibitors, including SAHA and TSA (Somoza et al., 2004; Vannini et al., 2004) . As there is an approximately 35% homology between class-I human HDACs (such as HDAC8) and AA-HDACs, we constructed a homology model for human HDAC1-3 using the AA-HDAC-SAHA and HDAC8-SAHA structures. As a control, we compared the predicted structure for the HDAC8-SAHA complex with the X-ray structure (Somoza et al., 2004) . The agreement between the two structures was found to be excellent (r.m.s.d. ¼ 1.775 Å for backbone atoms), and we therefore concluded that our computational models for HDAC1-3 were reliable enough to warrant further analysis of the general geometric features of class-I human HDACs.
We have observed that, in all cases, there is a hydrophobic channel that connects the periphery with the active sites of these enzymes, consistent with the structural data obtained with AA-HDAC and HDAC8 ( Figure 1a ) (Finnin et al., 1999; Somoza et al., 2004; Vannini et al., 2004) . These active sites consist of a zinc (II) cation surrounded by three coordinating residuestwo aspartates and one histidine. Finally, there are other channels in AA-HDAC, the function of which is thought to be associated with the exit of the hydrolysis by product, namely, the acetate anion (Wang et al., 2004) (Figure 1a) .The currently reported HDAC inhibitors, such as SAHA or TSA, share the following common features (Villar-Garea and Esteller, 2004) (Figure 1b) : (i) a zinc-chelating group, for example, hydroxamic acid; (ii) a linear hydrophobic chain that mimics the 1,4-butylene alkyl chain of the lysine residue present in the natural substrates of HDACs and (iii) a filling cap, usually an aromatic or heteroaromatic ring that fills the entrance to the hydrophobic channel. On the basis of our structural analysis of class-I human HDACs, we concluded that there are at least three possible interaction modes that could improve the binding of the inhibitors (Figure 1c ): (i) An acidic residue at the edge of the hydrophobic channel, consisting of an aspartate residue; (ii) several shallow cavities surrounding the entrance to the channel, made up of hydrophobic and aromatic residues and (iii) basic groups close to this entrance, consisting of lysine, arginine or histidine residues, depending on the class-I HDAC under consideration. On this basis, we reasoned that an expanded subfamily of inhibitors could be generated, taking into account the general features shown in Figure 1c .
Suitable candidates for fulfilling the requirements outlined above are the (1H)-pyrroles illustrated in Figure 1d . The pyrrole nucleus has already been studied for the design of HDAC inhibitors (Massa et al. 2001; Maier et al., 2006) . We synthesized 3,5-diaryl-1H-pyrrole-2-carboxamide derivatives (compounds 6a-l) by means of the sequence of reactions illustrated in Figure 1d . The key step in the chemical synthesis relies on a (3 þ 2) thermal cycloaddition between nitroalkenes 1 and the azomethine ylides derived from imines 2 (Vivanco et al., 2000) . The mixture of endo-and exo-3 cycloadducts was aromatized in the presence of MnO 2 to yield the corresponding (1H)-pyrroles 4 and 5 in 1:2 ratio. Deprotection of the methyl ester groups and coupling with the appropriate e-amino ester yielded the corresponding amides possessing two NH groups amenable to coordination with the aforementioned aspartate residues (Figure 2a ). Most importantly, docking experiments of compound 6h showed excellent binding energies and showed, in addition to the stabilizing interactions with the zinc (II) cation and the tyrosine and histidine residues of the HDACs (Figure 2b ), the expected stabilizing interactions with the aspartates and basic residues at the entrance of the hydrophobic channel, as well as favorable hydrophobic and p-stacking interactions with the groups surrounding the entrance to this channel. Further elaboration produced the corresponding hydroxamic acids (compounds 6c, 6d, 6g, 6h, 6k and 6l). It is noteworthy that the designed synthesis is convergent and versatile, and is well suited to further optimization through focused chemical libraries. In addition, it should be noted that the type 6 compounds fulfill the bioavailability requirements for pharmacologically promising compounds (Lipinski et al., 2001) .
The next step was to show that these compounds were indeed active HDAC inhibitors with important biological effects, such as the inhibition of cell proliferation. To this end, we chose the initial biological model of human cancer cell lines, in which it is recognized that histone acetylation patterns are altered (Esteller, 2007) , a potential for translational application exists (VillarGarea and Esteller, 2004; Balakin et al., 2007) and the classic HDAC inhibitor SAHA can be used as a reference drug (Marks, 2007) . Among compounds 6a-l (Figure 1d ), the hydroxamic acid compounds, 6h and 6l, were the most active molecules. They inhibited HDAC enzymatic activity in nuclear extracts from the colon cancer cell line ,HCT116, and in the T-cell leukemia ,MOLT-4, in a dose-dependent manner (Figure 3a) . The analysis of the acetylation levels of histones H3 and H4 by western blotting using specific antibodies raised against tetra-acetylated peptides for each histone showed that 1 mM of both 6h and 6l was enough to hyperacetylate histones H3 and H4 (Figure 3b) . Quantification of histone acetylation by high-performance capillary electrophoresis (HPCE) upon 6h and 6l treatment also confirmed the induction of histone hyperacetylation (Supplementary Figure 1) . From a gene-base standpoint, both 6h and 6l were able to induce the expression of p21 WAF1/CIP1 and gelsolin (Figure 3c) , two of the best-characterized target genes upregulated by HDAC inhibitors in cancer cell lines (Villar-Garea and Esteller, 2004; Marks, 2007) .
Once the biochemical effects of type 6 compounds as HDAC inhibitors had been confirmed, we assessed their effects on cancer cell biology. We observed that both 6h and 6l inhibited cancer-cell growth dose-dependently. MOLT4 cells were the most sensitive to type 6 compound treatment, yielding IC 50 values of 0.47 ± 0.15 and 0.39 ± 0.06 mM for 6h and 6l, respectively, whereas for HCT116 cells IC 50 values were 0.6 ± 0.07 and 0.62 ± 0.02 mM (Figure 4a ),respectively. Interestingly, the sensitivity to compounds 6h and 6l was similar to that observed for SAHA: IC 50 values of 0.44 ± 0.09 (MOLT4) and 0.82 ± 0.11 mM (HCT-116), respectively ( Figure 4a ). The described inhibition of cell proliferation induced by compounds 6h and 6l was associated with the induction of apoptosis and cell-cycle arrest at G2/M (Figure 4b and Supplementary Figure 2) .
The current development of efficient anticancer drugs must take into account all the crucial steps in tumor development and metastasis, among them the targeting of new blood vessel formation (Folkman, 2007) . HDAC inhibitors have shown some antiangiogenic potential (Kim et al., 2001) , although this has yet to be fully explored. Thus, we wondered whether the newly identified HDAC inhibitor 6 could act as blocking agents against angiogenesis. We found that compounds 6h and 6l were inhibitors of angiogenesis in the chicken embryo aortic arch ring assay (Figure 4c ) and in the directed in vivo angiogenesis assay (DIVAA) (Figure 4c) . Furthermore, treatment of MOLT-4 and HCT-116 with the aforementioned molecules 6h and 6l also significantly reduced the mRNA expression of two critical angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor (bFGF) (Supplementary Figure 3) . Thus, compounds 6h and 6l, in addition to their antiproliferative and proapoptotic features, also have an antiangiogenic capacity that could be extremely useful for therapeutic purposes.
We transferred our experiments from the in vitro assays described above to in vivo and ex vivo settings in mice and human models, respectively. For the mouse experiments, nude animals were s.c. injected with . In all cases, the surfaces were generated with a probe radius of 0.14 nm (water). The color code for the residues is: red, acidic; green, hydrophobic; dark blue, basic; light blue, polar. (b) Tube representation of 6h docked to human HDAC1. The main stabilizing interactions with selected residues of HDAC1 are shown.
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A Zubia et al MOLT4 or HCT116 and treated with compound 6h, compound 6l or the vehicle substance dimethyl sulfoxide (DMSO). Both compounds exhibited significant antitumoral activity in the xenotransplanted mice: MOLT4 and hematocrit (HCT)116 xenografts were five and three times larger, respectively, in the control DMSO group than in those observed in the groups receiving the HDAC inhibitors (Figure 5a ). Finally, and of most clinical relevance, we studied the proapoptotic potential of the HDAC inhibitors 6h and 6l in ex vivo assays of B-cell chronic lymphocytic leukemia (CLL). This disease is characterized by the accumulation of long- lived B-lymphocytes (Chiorazzi et al., 2005) . Ideally, proapoptotic chemotherapeutic agents should not affect the non-transformed accompanying T-lymphocytes. We observed that treatment with compounds 6h or 6l (2 mM) reduced the percentage of viable CLL cells to 32.4 ± 17.3% or 21.5 ± 13.1% of the original values, respectively. In contrast, with the same treatment, the viable T-cells were reduced to 61.1±18.2% or 50.6±18.8% of their original values, respectively (Figure 5b ). The proapoptotic effects in the B-cells were associated with the induction of hyperacetylation of histones H3 and H4 (Figure 5c ). Overall, these results indicate that malignant B-cells are more sensitive than non-transformed T-cells to the induction of apoptosis by compounds 6h and 6l. In summary, we have described a novel subfamily of HDAC inhibitors, 5-diaryl-1H-pyrrole-2-carboxamide derivatives, with powerful in vitro, ex vivo and in vivo activities at the biochemical and cellular levels with a promising potential antitumoral use. 
